Modality
Degrader
MOA
GLP-1/GIP
Target
PLK4
Pathway
RAS/MAPK
MDSALSCrohn's
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Aug 2031
Phase 1Current
NCT04702623
578 pts·MDS
2018-02→2028-07·Terminated
NCT06207874
2,890 pts·Crohn's
2020-03→2031-08·Recruiting
3,468 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-11-107mo awayConference· ALS
2028-07-212.3y awayInterim· MDS
2031-08-255.4y awayInterim· Crohn's
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Termina…
P1
Recruit…
Catalysts
Conference
2026-11-10 · 7mo away
ALS
Interim
2028-07-21 · 2.3y away
MDS
Interim
2031-08-25 · 5.4y away
Crohn's
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04702623 | Phase 1 | MDS | Terminated | 578 | eGFR |
| NCT06207874 | Phase 1 | Crohn's | Recruiting | 2890 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 |